Literature DB >> 21636719

Fanconi anemia (FA)-associated 3q gains in leukemic transformation consistently target EVI1, but do not affect low TERC expression in FA.

Stefan Meyer, Claire Bristow, Mark Wappett, Stuart Pepper, Anthony D Whetton, Helmut Hanenberg, Heidemarie Neitzel, Marcin W Wlodarski, Wolfram Ebell, Holger Tönnies.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21636719     DOI： 10.1182/blood-2011-03-343897

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

Review 1.  Molecular pathogenesis and clinical management of Fanconi anemia.

Authors:  Younghoon Kee; Alan D D'Andrea
Journal:  J Clin Invest       Date:  2012-11-01       Impact factor: 14.808

2.  Detectable clonal mosaicism in blood as a biomarker of cancer risk in Fanconi anemia.

Authors:  Judith Reina-Castillón; Roser Pujol; Marcos López-Sánchez; Benjamín Rodríguez-Santiago; Miriam Aza-Carmona; Juan Ramón González; José Antonio Casado; Juan Antonio Bueren; Julián Sevilla; Isabel Badel; Albert Català; Cristina Beléndez; María Ángeles Dasí; Cristina Díaz de Heredia; Jean Soulier; Detlev Schindler; Luis Alberto Pérez-Jurado; Jordi Surrallés
Journal:  Blood Adv       Date:  2017-01-23

3.  Chromosomal Aberrations and Survival after Unrelated Donor Hematopoietic Stem Cell Transplant in Patients with Fanconi Anemia.

Authors:  Youjin Wang; Weiyin Zhou; Blanche P Alter; Tao Wang; Stephen R Spellman; Michael Haagenson; Meredith Yeager; Stephanie J Lee; Stephen J Chanock; Sharon A Savage; Shahinaz M Gadalla
Journal:  Biol Blood Marrow Transplant       Date:  2018-06-04       Impact factor: 5.742

Review 4.  Patients with Fanconi anemia and AML have different cytogenetic clones than de novo cases of AML.

Authors:  Andrzej Rochowski; Susan B Olson; Todd A Alonzo; Robert B Gerbing; Beverly J Lange; Blanche P Alter
Journal:  Pediatr Blood Cancer       Date:  2012-04-19       Impact factor: 3.167

Review 5.  Mechanisms of somatic transformation in inherited bone marrow failure syndromes.

Authors:  Haruna Batzorig Choijilsuren; Yeji Park; Moonjung Jung
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 6.  Somatic mosaicism in inherited bone marrow failure syndromes.

Authors:  Fernanda Gutierrez-Rodrigues; Sushree S Sahoo; Marcin W Wlodarski; Neal S Young
Journal:  Best Pract Res Clin Haematol       Date:  2021-06-27       Impact factor: 3.670

Review 7.  Significance of Clonal Mutations in Bone Marrow Failure and Inherited Myelodysplastic Syndrome/Acute Myeloid Leukemia Predisposition Syndromes.

Authors:  Eva J Schaefer; R Coleman Lindsley
Journal:  Hematol Oncol Clin North Am       Date:  2018-05-01       Impact factor: 3.722

8.  Chromosomal aberrations associated with clonal evolution and leukemic transformation in fanconi anemia: clinical and biological implications.

Authors:  Stefan Meyer; Heidemarie Neitzel; Holger Tönnies
Journal:  Anemia       Date:  2012-05-23

9.  Phosphorylation of the leukemic oncoprotein EVI1 on serine 196 modulates DNA binding, transcriptional repression and transforming ability.

Authors:  Daniel J White; Richard D Unwin; Eric Bindels; Andrew Pierce; Hsiang-Ying Teng; Joanne Muter; Brigit Greystoke; Tim D Somerville; John Griffiths; Simon Lovell; Tim C P Somervaille; Ruud Delwel; Anthony D Whetton; Stefan Meyer
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

10.  EVI1 carboxy-terminal phosphorylation is ATM-mediated and sustains transcriptional modulation and self-renewal via enhanced CtBP1 association.

Authors:  Roberto Paredes; Marion Schneider; Adam Stevens; Daniel J White; Andrew J K Williamson; Joanne Muter; Stella Pearson; James R Kelly; Kathleen Connors; Daniel H Wiseman; John A Chadwick; Harald Löffler; Hsiang Ying Teng; Simon Lovell; Richard Unwin; Henri J van de Vrugt; Helen Smith; Olga Kustikova; Axel Schambach; Tim C P Somervaille; Andrew Pierce; Anthony D Whetton; Stefan Meyer
Journal:  Nucleic Acids Res       Date:  2018-09-06       Impact factor: 16.971
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.